TY - JOUR
T1 - Human immunodeficiency virus-related non-Hodgkin lymphoma
T2 - Activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients
AU - Spina, Michele
AU - Vaccher, Emanuela
AU - Juzbasic, Senka
AU - Milan, Isabella
AU - Nasti, Guglielmo
AU - Talamini, Renato
AU - Fasan, Marco
AU - Antinori, Andrea
AU - Nigra, Ezio
AU - Tirelli, Umberto
PY - 2001/7/1
Y1 - 2001/7/1
N2 - BACKGROUND. The prognosis of patients with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) is poor. In fact, despite a high complete response (CR) rate, approximately 50% of these patients die from progressive lymphoma. METHODS. From November 1994 to April 2000, the authors treated 40 patients with resistant or recurrent HIV-related NHL with a 96-hour continuous intravenous infusion of cyclophosphamide (187.5 mg/m2 per day), doxorubicin (12.5 mg/m2 per day), and etoposide (60 mg/m2 per day). RESULTS. The median number of cycles administered was two (range, one to six cycles). A CR was documented in 4 of 40 patients (10%), and a partial remission (PR) was documented in 7 of 40 patients (18%). The CR median duration was 6 months (range, 4-30+ months), whereas PRs lasted for 5 months (range, 2-8 months). The overall median survival was 4 months (range, <1-33 months), and the median survival for responding patients was 10 months. CONCLUSIONS. The current data confirm that infusional cyclophosphamide, doxorubicin, and etoposide is active in patients with refractory or recurrent HIV-related NHL. However, the median survival of these patients remains poor, and the other innovative approaches should be used.
AB - BACKGROUND. The prognosis of patients with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) is poor. In fact, despite a high complete response (CR) rate, approximately 50% of these patients die from progressive lymphoma. METHODS. From November 1994 to April 2000, the authors treated 40 patients with resistant or recurrent HIV-related NHL with a 96-hour continuous intravenous infusion of cyclophosphamide (187.5 mg/m2 per day), doxorubicin (12.5 mg/m2 per day), and etoposide (60 mg/m2 per day). RESULTS. The median number of cycles administered was two (range, one to six cycles). A CR was documented in 4 of 40 patients (10%), and a partial remission (PR) was documented in 7 of 40 patients (18%). The CR median duration was 6 months (range, 4-30+ months), whereas PRs lasted for 5 months (range, 2-8 months). The overall median survival was 4 months (range, <1-33 months), and the median survival for responding patients was 10 months. CONCLUSIONS. The current data confirm that infusional cyclophosphamide, doxorubicin, and etoposide is active in patients with refractory or recurrent HIV-related NHL. However, the median survival of these patients remains poor, and the other innovative approaches should be used.
KW - Chemotherapy
KW - Human immunodeficiency virus infection
KW - Non-Hodgkin lymphoma
KW - Second-line treatment
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0035397512&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035397512&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(20010701)92:1<200::AID-CNCR1310>3.0.CO;2-A
DO - 10.1002/1097-0142(20010701)92:1<200::AID-CNCR1310>3.0.CO;2-A
M3 - Article
C2 - 11443628
AN - SCOPUS:0035397512
VL - 92
SP - 200
EP - 206
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 1
ER -